Tags

Type your tag names separated by a space and hit enter

Endocannabinoid and Prostanoid Crosstalk in Pain.
Trends Mol Med. 2019 10; 25(10):882-896.TM

Abstract

Interfering with endocannabinoid (eCB) metabolism to increase their levels is a proven anti-nociception strategy. However, because the eCB and prostanoid systems are intertwined, interfering with eCB metabolism will affect the prostanoid system and inversely. Key to this connection is the production of the cyclooxygenase (COX) substrate arachidonic acid upon eCB hydrolysis as well as the ability of COX to metabolize the eCBs anandamide (AEA) and 2-arachidonoylglycerol (2-AG) into prostaglandin-ethanolamides (PG-EA) and prostaglandin-glycerol esters (PG-G), respectively. Recent studies shed light on the role of PG-Gs and PG-EAs in nociception and inflammation. Here, we discuss the role of these complex systems in nociception and new opportunities to alleviate pain by interacting with them.

Authors+Show Affiliations

Bioanalysis and Pharmacology of Bioactive Lipids Research Group, Louvain Drug Research Institute, Université Catholique de Louvain, 1200 Bruxelles, Belgium.Bioanalysis and Pharmacology of Bioactive Lipids Research Group, Louvain Drug Research Institute, Université Catholique de Louvain, 1200 Bruxelles, Belgium.Bioanalysis and Pharmacology of Bioactive Lipids Research Group, Louvain Drug Research Institute, Université Catholique de Louvain, 1200 Bruxelles, Belgium.Bioanalysis and Pharmacology of Bioactive Lipids Research Group, Louvain Drug Research Institute, Université Catholique de Louvain, 1200 Bruxelles, Belgium. Electronic address: giulio.muccioli@uclouvain.be.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

31160168

Citation

Buisseret, Baptiste, et al. "Endocannabinoid and Prostanoid Crosstalk in Pain." Trends in Molecular Medicine, vol. 25, no. 10, 2019, pp. 882-896.
Buisseret B, Alhouayek M, Guillemot-Legris O, et al. Endocannabinoid and Prostanoid Crosstalk in Pain. Trends Mol Med. 2019;25(10):882-896.
Buisseret, B., Alhouayek, M., Guillemot-Legris, O., & Muccioli, G. G. (2019). Endocannabinoid and Prostanoid Crosstalk in Pain. Trends in Molecular Medicine, 25(10), 882-896. https://doi.org/10.1016/j.molmed.2019.04.009
Buisseret B, et al. Endocannabinoid and Prostanoid Crosstalk in Pain. Trends Mol Med. 2019;25(10):882-896. PubMed PMID: 31160168.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Endocannabinoid and Prostanoid Crosstalk in Pain. AU - Buisseret,Baptiste, AU - Alhouayek,Mireille, AU - Guillemot-Legris,Owein, AU - Muccioli,Giulio G, Y1 - 2019/05/31/ PY - 2019/03/12/received PY - 2019/04/18/revised PY - 2019/04/22/accepted PY - 2019/6/5/pubmed PY - 2020/6/27/medline PY - 2019/6/5/entrez KW - FAAH KW - MAGL KW - PGD2-G KW - bioactive lipid KW - inflammation KW - prostamide SP - 882 EP - 896 JF - Trends in molecular medicine JO - Trends Mol Med VL - 25 IS - 10 N2 - Interfering with endocannabinoid (eCB) metabolism to increase their levels is a proven anti-nociception strategy. However, because the eCB and prostanoid systems are intertwined, interfering with eCB metabolism will affect the prostanoid system and inversely. Key to this connection is the production of the cyclooxygenase (COX) substrate arachidonic acid upon eCB hydrolysis as well as the ability of COX to metabolize the eCBs anandamide (AEA) and 2-arachidonoylglycerol (2-AG) into prostaglandin-ethanolamides (PG-EA) and prostaglandin-glycerol esters (PG-G), respectively. Recent studies shed light on the role of PG-Gs and PG-EAs in nociception and inflammation. Here, we discuss the role of these complex systems in nociception and new opportunities to alleviate pain by interacting with them. SN - 1471-499X UR - https://www.unboundmedicine.com/medline/citation/31160168/Endocannabinoid_and_Prostanoid_Crosstalk_in_Pain_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1471-4914(19)30098-X DB - PRIME DP - Unbound Medicine ER -